Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents  

作　　者：Bill E. Cham 

机构地区：[1]Australasian Institute of Medical Research, Brisbane, Australia

出　　处：《Modern Chemotherapy》2013年第2期33-49,共17页化疗（英文）

摘　　要：In the last century, the discovery of cytotoxic agents was revolutionary for anticancer therapy. These therapies have resulted in better understanding of cancer in general. However, the development of agents that combine efficacy, safety and convenience remains a great challenge. The narrow, if not adverse, therapeutic index of most drugs, the damage not only to cancer cells, but also to normal and healthy tissue and the occurrence of resistance have limited anticancer efficacy. This review presents the development of promising novel cytotoxic solasodine rhamnosyl glycoside drugs that offer not only gains in specificity and efficacy, but also in safety, tolerability, non-resistance and convenience in the treatment of patients with cancer.In the last century, the discovery of cytotoxic agents was revolutionary for anticancer therapy. These therapies have resulted in better understanding of cancer in general. However, the development of agents that combine efficacy, safety and convenience remains a great challenge. The narrow, if not adverse, therapeutic index of most drugs, the damage not only to cancer cells, but also to normal and healthy tissue and the occurrence of resistance have limited anticancer efficacy. This review presents the development of promising novel cytotoxic solasodine rhamnosyl glycoside drugs that offer not only gains in specificity and efficacy, but also in safety, tolerability, non-resistance and convenience in the treatment of patients with cancer.

关 键 词：CANCER Skin CANCER SOLAMARGINE Solasonine BEC SOLASODINE Rhamnosyl GLYCOSIDES CuradermBEC5 Apoptosis ANTINEOPLASTIC Targeted Therapy 

分 类 号：R73[医药卫生—肿瘤]